Prostaglandin F2-alpha (PGF2α) in Vitiligo

N/AUnknownNCT03755830

Cairo University60 enrolled

Overview

study the cutaneous expression of PGF2α in vitiligo patients and compare it with normal control subjects.

Measurement of tissue levels of PGF2α in vitiligo patients and compare them with healthy controls.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Vitiligo

Interventions

Skin biopsyOTHER

Two skin biopsies (lesional and non-lesional) will be taken from every patient. Also a skin biopsy will be taken from each control subject.

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with non-segmental vitiligo. * Both sexes. * Age \< 18 years old. * New cases or cases not receiving any medications for at least 3 months ago. Exclusion Criteria: * Age: Patients \< 18 years. * Segmental or universal vitiligo. * Pregnant and lactating females.

Outcomes

Primary Outcomes

Measurement of tissue levels of PGF2α in vitiligo patients and compare them with healthy controls.

Measurement of tissue levels of PGF2α in vitiligo patients and compare them with healthy controls to study and verify the hypothesis of involvement of PGF2α in the pathogenesis of vitiligo.• Skin biopsy for assessment of tissue levels of the PGF2α will be taken from both lesional and non lesional skin of patients of vitiligo and from normal skin of healthy controls. All skin biopsies are from non-sun exposed sites.

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.